[Results of XXXX Repair (EVAR)].

@entity1 @entity1070 @entity1188 @entity1028 @entity1756
Endovascular surgery for @entity1028 ( @entity1028 ) has been performed with different commercially available devices since more than 7 years. The technique of implantation even for @entity1756 is feasible. Attention is now focused on complications and mid-term results. We present a single center experience over the last 7 years using nine different endografts. 653 @entity1 with AAAs were treated endovascularly (158 tubes, 495 bifurcated) between August 1994 and September 2001. The total mortality rate in the follow-up period (median 37 months) was 6.1 % with a 30-day mortality of 0.76 % and a procedure-related lethality of 1.2 %. Tube endografts showed the highest endoleakage rate (37.3 %) due to secondary shortening, migration and material defects. Endoleakage was diagnosed in 18.2 % of unibody designed stentgrafts versus 28.3 % in modular grafts. Regarding proximal Type I endoleaks suprarenal fixation with uncovered stents seems to be of no further advantage in proximal graft fixation. The conversion rate was 6.6 % (n = 43), @entity1756 following endovascular repair occurred in 3 of these @entity1 (0.45 %). Mortality in emergency conversion was 30 % compared to no deaths in elective cases. There was a surprisingly high rate of inadvertent renal @entity1188 (9 %) in follow-up CT scans, two times higher in suprarenal fixation (18 %) than in infrarenal position (7.4 %). In conclusion, we observed best results in unibody bifurcated stentgrafts, late failure of first generation endografts (Mintec(R)) and decreasing conversion rates over the last years (learning curve!). The clinical significance of a side @entity1070 and related maximal @entity1028 diameter remains uncertain. The ideal graft has yet to be found, but improvements in design and implantation techniques evolve rapidly. Good results will be obtained in the future by @entity1 selection and restrictive indications.
